Cardinal Health在季度收益大幅上涨、指引上调后股价飙升

2026-02-05 23:15

Cardinal Health (CAH) is up ~10% in Thursday morning trading after posting fiscal 2026 Q2 results that beat on both lines as well as boosting full-year EPS guidance.
The drug wholesaler now sees non-GAAP diluted EPS for FY26 of $10.15 to $10.35, up from $9.65-$9.85 prior. The consensus is $10.02.
In Q2, non-GAAP diluted EPS of $2.63 compares to $1.93 in the year-ago period.
Cardinal was helped in the quarter by 19% year-over-year revenue growth in its largest segment, pharmaceutical and specialty solutions, to $60.7B.
The company ended 2025 with cash and equivalents of ~$2.8B compared to ~$3.9B on June 30, 2025.
Cardinal rivals Cencora (COR) and and McKesson (MCK) are both up significantly following their earnings releases on Feb. 4.

More on Cardinal Health